According to Zhitong Financial App News, Hanson Pharmaceuticals (03692.HK) announced that the monotherapy for ametinib (overseas product name: Aumseqa®) was approved for listing in the European Union (EU) after the European Medicines Agency (EMA) Human Medicines Committee (CHMP) issued an implementation decision on September 25, 2026. The European Commission (EC) General Directorate of Health and Food Safety issued an implementation decision on September 25, 2026.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.